Key result
Treatment with alteplase and heparin followed by oral anticoagulants successfully dissolved coronary aneurysm thromboses in 4 young male Kawasaki disease patients.
Why the study?
Ischemic cardiomyopathy caused by thrombosis is the most severe complication of giant coronary aneurysm in children with Kawasaki disease, and adding Alteplase may provide efficient thrombolysis.
Does alteplase-based thrombolytic therapy dissolve coronary aneurysm thrombosis in pediatric Kawasaki disease patients?
Case Report (n=4)
No
Does alteplase-based thrombolytic therapy dissolve coronary aneurysm thrombosis in pediatric Kawasaki disease patients?
Alteplase combined with anticoagulation and antiplatelet therapy may effectively dissolve coronary aneurysm thromboses in pediatric Kawasaki disease patients, even beyond 12 hours of occurrence.
May support adjunctive alteplase in select KD thrombosis cases; leaves open confirmation in prospective trials.
OBJECTIVE: The most severe complication associated with giant coronary aneurysm in children with Kawasaki disease is ischemic cardiomyopathy (ICM) caused by thrombosis. Addition of tissue plasminogen activator, Alteplase, in the treatment regimen can be an efficient thrombolytic therapy, and therefore can have a significantly positive impact on patients' quality of life in long term. METHODS: Total four male KD patients with central thromboses in coronary aneurysm were treated in Pediatric Cardiology Department of Shengjing Hospital, China Medical University, from January 2020 to August 2021. These patients received thrombolytic treatments including Alteplase once + Heparin for 1 week followed by continuous oral Warfarin + Aspirin + Clopidogrel. RESULTS: 4 young male KD patients had coronary aneurysm (CAA) complicated with total 7 occurrences of central thrombosis. These patients were given alteplase and heparin/oral Warfarin + Aspirin + Clopidogrel treatment. 9 days to 2 months later, thromboses were significantly dissolved. The treatment successfully diminished the thrombosis complication. CONCLUSION: 1. Pediatric KD patients complicated with coronary aneurysm thrombosis are prone to recurrence of thrombosis. 2. In KD patients complicated with coronary aneurysm thrombosis, treatments described in Method can be used for treating either small thromboses formed less than 1 month with strong echo and convex lumen or large thromboses with mixed strong and weak echo. With these treatments, coronary artery blood flow can be improved or completely recovered. 3. Clinical experiences at our center in treating these KD patients suggest that Alteplase can be considered in thrombolytic treatment beyond the limitation of less than 12 h of thrombosis occurrence.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2022) conducted a case report in Kawasaki disease with coronary aneurysm thrombosis (n=4). Alteplase-based thrombolytic therapy was evaluated on Thrombosis dissolution. Treatment with alteplase and heparin followed by oral anticoagulants successfully dissolved coronary aneurysm thromboses in 4 young male Kawasaki disease patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: